Genetics: Update on Prenatal Screening and Diagnosis

Obstetrics and Gynecology Clinics of North America

Volumn 42, Issue 2, 2015, Pages 193-208

  Evans, Mark I ^a,b   Andriole, Stephanie ^a   Evans, Shara M ^a  

^a PLLC and Fetal Medicine Foundation of America ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Amniocentesis; Chorionic villus sampling; Chromosomal; Fetal reduction; Genetic disorder; Mendelian; Multiple pregnancies; Pre implantation diagnosis

Indexed keywords

AMNIOCENTESIS; AMNION BAND SYNDROME; AMNIOTIC FLUID CELL; CELL FREE SYSTEM; CHORION VILLUS SAMPLING; CHROMOSOME DISORDER; CYTOGENETICS; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC COUNSELING; GENETIC DISORDER; GESTATIONAL AGE; HUMAN; MATERNAL BLOOD; MENDELIAN DISORDER; MICROARRAY ANALYSIS; MOSAICISM; NERVOUS SYSTEM INJURY; PATIENT SAFETY; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SEQUENCE ANALYSIS; TREATMENT INDICATION; ADULT; CONGENITAL ABNORMALITIES; FEMALE; GENETIC DISEASES, INBORN; GENETIC MARKER; MATERNAL AGE; MULTIPLE PREGNANCY; NEWBORN; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PROCEDURES; PSYCHOLOGY; TRENDS;

GENETIC MARKER;

ADULT; AMNIOCENTESIS; CHORIONIC VILLI SAMPLING; CONGENITAL ABNORMALITIES; FEMALE; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC MARKERS; HUMANS; INFANT, NEWBORN; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY, MULTIPLE; PRENATAL DIAGNOSIS;

EID: 84931425768     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2015.01.011     Document Type: Review

References (47)

1. Prenatal diagnosis: genetics, reproductive risks, testing, and management 2006, McGraw Hill Publishing Co, New York. M.I. Evans, M.P. Johnson, Y. Yaron (Eds.).
2. Ashkenazi Jewish carrier screening: integrated genetics. Available at:. Accessed February, 2015. https://www.labcorp.com/wps/portal/!ut/p/c1/04_SB8K8xLLM9MSSzPy8xBz9CP0os3h_U2cv30B_IwN_f3MDA88APyM_byN_Q3cfA30_j_zcVP2CbEdFAPxk0ls!/dl2/d1/L0lDU0lKSWdrbUEhIS9JRFJBQUlpQ2dBek15cXchL1lCSkoxTkExTkk1MC01RncvN19PNUNKTVFPMjBPTzcwMElQTjJOSzJPMUdENS9JX19fXzE!/?WCM_PORTLET=PC_7_O5CJMQO20OO700IPN2NK2O1GD5_WCM%26WCM_GLOBAL_CONTEXT=/wps/wcm/connect/IntGeneticsLib/integratedgenetics/home/our+services/reproductive+testing/aj-carrier-test.
3. Evans M.I., Cuckle H.S. Performance adjusted risks (PAR): a method to improve the quality of algorithm performance while allowing all to play. Prenat Diagn 2011, 31:797-801.
4. Srinivasan B.S., Evans E.A., Flannick J., et al. Auniversal carrier test for the long tail of Mendelian disease. Reprod Biomed Online 2010, 4:537-551.
5. National Human Genome Research Institute. Regulation of genetic tests. Available at:. Accessed February, 2015. http://www.genome.gov/10002335.
6. Martin J.A., Hamilton B.E., Osterman M.J., et al. Births: final data for 2012. Natl Vital Stat Rep 2015, 64(1):1-68.
7. Evans M.I., Hallahan T.W., Krantz D., et al. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. Am J Obstet Gynecol 2007, 196:198-205.
8. Hassan S., Romero R., Vidyadhari D., et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011, 38:18-31.
9. Benacerraf B.R., Nadel A., Bromley B. Identification of second trimester fetuses with autosomal trisomy by use of a sonographic scoring index. Radiology 1994, 193:135-140.
10. Lau T.K., Evans M.I. Second trimester sonographic soft markers: what can we learn from the experience of first trimester nuchal translucency screening?. Ultrasound Obstet Gynecol 2008, 32:123-125.
11. Wright D., Syngelaki A., Bradbury D., et al. First trimester screening for Trisomies 21, 18, and13 by ultrasound and biochemical testing. Fetal Diagn Ther 2014, 35:118-126.
12. Jacobson J.B., Barter R.H. Intrauterine diagnosis and management of genetic defects. Am J Obstet Gynecol 1967, 99:795-801.
13. Souka A.P., Von Kaisenberg C.S., Hyett J.A., et al. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005, 192:1005-1021.
14. Wapner R.J., Martin C.L., Levy B., et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. NEngl J Med 2012, 367:2175-2184.
15. Bianchi D.W., Simpson J.L., Jackson L.G., et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. Prenat Diagn 2002, 22:609-615.
16. Lo Y.M., Corbetta N., Chamberlain P.F., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350:485-487.
17. Lo Y.M. Noninvasive prenatal detection of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis: a review of the current state of the art. BJOG 2009, 116:152-157.
18. Ehrich M., Deciu C., Zwiefelhofer T., et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011, 204:205.e1-205.e11.
19. Sparks A.B., Wang E.T., Struble C.A., et al. Selective analysis of cell free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012, 32:3-9.
20. Bianchi D.W., Wilkins-Haug L. Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road?. Clin Chem 2014, 60:78-87.
21. Chitty L.S., Bianchi D.W. Noninvasive prenatal testing: the paradigm is shifting rapidly. Prenat Diagn 2013, 33:511-513.
22. Galen R.S., Gambino S.R. Beyond normality: the predictive value and efficacy of medical diagnoses 1975, MD John Wiley and Sons, Baltimore (MD).
23. Krantz D.A., Hallahan T.W., Carmichael J.B., et al. Utilization of a 1/1000 cutoff in combined screening for Down Syndrome in younger women AMA patients provides cost advantages compared with NIPS. Am J Obstet Gynecol 2014, 210:S111.
24. Cuckle H.S., Benn P., Pergament E. Maternal cfDNA screening for Down syndrome - a cost sensitivity analysis. Prenat Diagn 2013, 33:636-642.
25. Evans M.I., Sonek J., Hallahan T., et al. Cell-free fetal DNA screening in the USAnited States: a cost analysis of screening strategies. Ultrasound Obstet Gynecol 2015, 45:74-83.
26. Fletcher J.C., Evans M.I. Maternal bonding in early fetal ultrasound examinations. NEngl J Med 1983, 308:392-393.
27. Hanson F.W., Happ R.L., Tennant F.R., et al. Ultrasonography-guided early amniocentesis in singleton pregnancies. Am J Obstet Gynecol 1990, 162:1376-1381.
28. Wilson R.D. Early amniocentesis: a clinical review. Prenat Diagn 1995, 15:1259-1273.
29. Van der Pol J.S., Wolf H., Boer K., et al. Jejunal atresia related to the use of methylene blue in genetic amniocentesis in twins. Br J Obstet Gynaecol 1992, 99:141-143.
30. Drugan A., Sokol R.J., Syner F.N., et al. Clinical implications of amniotic fluid AFP in twin pregnancies. JReprod Med 1989, 34:977-981.
31. Mujezinovic F., Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villus sampling: a systematic review. Obstet Gynecol 2007, 110:687-694.
32. Tabor A., Phillip J., Masden M., et al. Randomized controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986, 1:1287-1293.
33. Eddleman K.A., Malone F.D., Sullivan L., et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006, 108:1067-1072.
34. Squier M., Chamberlain P., Zaiwalla Z., et al. Five cases of brain injury following amniocentesis in mid-term pregnancy. Dev Med Child Neurol 2000, 42(8):554-560.
35. Rosner M., Pergament E., Andriole S., et al. Detection of genetic abnormalities using CVS and FISH prior to fetal reduction in sonographically normal appearing fetuses. Prenat Diagn 2013, 33:940-944.
36. Evans M.I., Rozner G., Yaron Y., et al. CVS in Evans MI. Prenatal diagnosis: genetics, reproductive risks, testing, and management 2006, 433-442. McGraw Hill Publishing Co, New York. M.P. Johnson, Y. Yaron (Eds.).
37. Silverman N.S., Sullivan M.W., Jungkind D.L., et al. Incidence of bacteremia associated with chorionic villus sampling. Obstet Gynecol 1994, 84(6):1021-1024.
38. Akolekar R., Beta J., Picciarelli G., et al. Procedure related risk of misscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015, 45:16-26.
39. Wulff R, Tabor A. Risk of fetal loss from invasive testing. Presented at the meeting of Fetal Medicine Foundation. 2013.
40. Rhoads G.G., Jackson L.G., Schlesselman S.E., et al. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. NEngl J Med 1989, 320:609.
41. Ledbetter D.H., Zachary J.L., Simpson M.S., et al. Cytogenetic results from the US collaborative study on CVS. Prenat Diagn 1992, 12(5):317.
42. van Ommen G.J., Breuning M.H., Raap A.K. FISH in genome research and molecular diagnostics. Curr Opin Genet Dev 1995, 5(3):304.
43. Evans M.I., Klinger K.W., Isada N.B., et al. Rapid prenatal diagnosis by fluorescent in situ hybridization of chorionic villi: an adjunct to long-term culture and karyotype. Am J Obstet Gynecol 1992, 167:1522.
44. Verlinsky Y., Cieslak J., Freidine M., et al. Polar body diagnosis of common aneuploidies by FISH. JAssist Reprod Genet 1996, 13:157-162. 100.
45. Manning M. Hudgins L Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 2010, 12(11):742-745.
46. Shaffer L.G., Dabell M.P., Fisher A.J., et al. Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. Prenat Diagn 2012, 32(10):976-985.
47. Handyside A.H., Robinson M.D., Simpson R.J., et al. Isothermal whole genome amplification from single and small numbers of cells: a new era for preimplantation genetic diagnosis of inherited disease. Mol Hum Reprod 2004, 10(10):767-772.